Ascendiant Capital Markets Comments on SXTP Q1 Earnings

60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) – Research analysts at Ascendiant Capital Markets issued their Q1 2027 earnings estimates for 60 Degrees Pharmaceuticals in a research report issued to clients and investors on Wednesday, May 20th. Ascendiant Capital Markets analyst L. Ward anticipates that the company will post earnings per share of ($0.90) for the quarter. Ascendiant Capital Markets has a “Buy” rating and a $3.70 price objective on the stock. The consensus estimate for 60 Degrees Pharmaceuticals’ current full-year earnings is ($3.16) per share. Ascendiant Capital Markets also issued estimates for 60 Degrees Pharmaceuticals’ Q2 2027 earnings at ($0.88) EPS, Q3 2027 earnings at ($0.91) EPS and Q4 2027 earnings at ($0.89) EPS.

A number of other analysts have also weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research report on Friday, March 27th. HC Wainwright lowered shares of 60 Degrees Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, May 20th. Finally, Wall Street Zen lowered shares of 60 Degrees Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, April 12th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, 60 Degrees Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $13.85.

60 Degrees Pharmaceuticals Price Performance

Shares of 60 Degrees Pharmaceuticals stock opened at $1.50 on Wednesday. 60 Degrees Pharmaceuticals has a fifty-two week low of $1.29 and a fifty-two week high of $14.68. The firm has a market capitalization of $3.99 million, a P/E ratio of -0.17 and a beta of 2.69. The company’s 50 day moving average price is $1.69 and its two-hundred day moving average price is $2.78.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last issued its earnings results on Friday, May 15th. The company reported ($1.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.52). The business had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.44 million.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.